[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,649
  • Shares Outstanding, K 34,647
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,850 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.59

Options Overview Details

View History
  • Implied Volatility 143.10% (+1.07%)
  • Historical Volatility 128.11%
  • IV Percentile 31%
  • IV Rank 10.78%
  • IV High 1,160.30% on 08/04/25
  • IV Low 20.18% on 01/06/26
  • Expected Move (DTE 2) 0.04 (1.77%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,374
  • Volume Avg (30-Day) 1,972
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 26,296
  • Open Int (30-Day) 21,606
  • Expected Range 2.36 to 2.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.54 +55.77%
on 04/10/26
2.42 -0.83%
on 05/06/26
+0.05 (+2.13%)
since 04/06/26
3-Month
1.54 +55.77%
on 04/10/26
3.03 -20.76%
on 03/17/26
-0.09 (-3.61%)
since 02/06/26
52-Week
1.44 +66.67%
on 05/07/25
5.50 -56.36%
on 11/28/25
+0.96 (+66.67%)
since 05/06/25

Most Recent Stories

More News
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated,...

ANVS : 2.40 (+5.73%)
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Financing secures path to first NDA submission for buntanetap 6-Month symptomatic data readout anticipated Q1 2027 Alzheimer’s disease Phase 3 trial 75% enrolled Parkinson's disease open-label...

ANVS : 2.40 (+5.73%)
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Publishes Historical Review of Buntanetap in The Scientist

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 2.40 (+5.73%)
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis...

ANVS : 2.40 (+5.73%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 2.70
2nd Resistance Point 2.56
1st Resistance Point 2.48
Last Price 2.40
1st Support Level 2.26
2nd Support Level 2.12
3rd Support Level 2.04

See More

52-Week High 5.50
Fibonacci 61.8% 3.95
Fibonacci 50% 3.47
Fibonacci 38.2% 2.99
Last Price 2.40
52-Week Low 1.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.